BIO-TECHNE Corp (TECH) community

TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30

Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value

$72.80−0.02 (-0.03%)

Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%

Community

Notes and questions about Bio-Techne from other investors

No posts about TECH yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Bio-Techne's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Nov 30, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TECH.

Compare: TECH vs RGEN · TECH vs QGEN · TECH vs ALVO · TECH vs TWST · TECH vs QDEL

Revenue growth0.9% · median 13.8%

Gross margin65.8% · median 52.0%

Operating margin19.6% · median -4.9%

Company	Revenue	Growth
QDEL	$2.59B	-4.5%
TECH	$1.23B	+0.9%
RGEN	$805.61M	+13.8%
TWST	$431.80M	+19.2%
QGEN	–	–
ALVO	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: June 30
Employees: 3,000
Held by institutions: 100.0%
Auditor: KPMG LLP
SEC CIK: 842023

Advertisement
300 × 250

See a number that looks wrong?